



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Design, Synthesis and Biological Evaluation of Novel Indazole Compounds with Potential Therapeutic Activity

A Thesis

Presented to

Faculty of Pharmacy, Dammanhour University

In Partial Fulfillment of the Requirements for the Degree of

Doctor of Philosophy

In

**Pharmaceutical Sciences
(Pharmaceutical Chemistry)**

By

Mahmoud Alaa El-Dine Mohamed Mokhtar Ragab

B. Pharm. Sci., 2009

M. Pharm. Sci. (Pharmaceutical Chemistry), 2014

**Department of Pharmaceutical Chemistry
Faculty of Pharmacy
Dammanhour University
Egypt**

2021

بسم الله الرحمن الرحيم



Advisors' Committee

Prof. Dr. Hoda G. Daabees

Professor of Pharmaceutical Chemistry

Prof. Dr. Khaled A. M. Abouzid

Professor of Pharmaceutical Chemistry

Dr. Mohamed M. Elagawany

Associate Professor of Pharmaceutical Chemistry

Dr. Shaymaa E. Kassab

Associate Professor of Medicinal Chemistry

**Department of Pharmaceutical Chemistry
Faculty of Pharmacy
Damanhour University
Egypt**

2021



Design, Synthesis, and Biological Evaluation of Novel Indazole Compounds with Potential Therapeutic Activity

A Thesis Presented to
Faculty of Pharmacy, Damanhour University
In Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
In Pharmaceutical Sciences
(Pharmaceutical Chemistry)

By

Mahmoud Alaa El-Dine Mohamed Mokhtar Ragab

B. Pharm. Sci., Faculty of Pharmacy, Alexandria University, 2009

M. Pharm. Sci., Faculty of Pharmacy, Alexandria University, 2014

Examiners' Committee:

Prof. Dr. Hoda G. Daabees

Professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Alexandria University

Prof. Dr. Safinaz El Sayed Abbas

Professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Cairo University

Prof. Dr. Khaled A. M. Abouzid

Professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Ain Shams University

Prof. Dr. Heba Attia Hamed Abd El Razik

Professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Alexandria University

Approved

.....

.....

.....

.....

Date / /2021



Advisors' Committee:

Prof. Dr. Hoda G. Daabees

Professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Damanhour University

Prof. Dr. Khaled A. M. Abouzid

Professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Ain Shams University

Dr. Mohamed M. Elagawany

Associate Professor of Pharmaceutical Chemistry
Faculty of Pharmacy, Damanhour University

Dr. Shaymaa Emam Kassab

Associate Professor of Medicinal Chemistry
Faculty of Pharmacy, Damanhour University

Approved

.....

.....

.....

.....

Department of Pharmaceutical Chemistry
Faculty of Pharmacy
Damanhour University
Egypt

2021

ACKNOWLEDGMENT

I acknowledge my advisor, Professor Khaled Abouzid, Prof. of pharmaceutical chemistry, His advice, suggestions, and directions that have positively influenced my academic career.

My deepest thanks to Professor Hoda Daabees, Prof. of pharmaceutical chemistry, for her patience and guidance throughout the course of my studies. Her support has allowed me to feel well equipped to tackle any problem, that I face throughout the work.

The final steps of my work would not have been possible without Dr. Mohamed Elagawany, Ass. Prof. of pharmaceutical chemistry, and the instruments he made available to me. Without his mentorship and incredible wealth of scientific expertise, the writing of this dissertation could never have been accomplished.

My gratitude extends to Dr. Shaymaa Kassab, Ass. Prof. of medicinal chemistry for her insightful comments and constructive criticisms.

I also thank my past and present chemistry mentors, particularly Professor Heba Attia, Prof. of pharmaceutical chemistry, who was influential in my academic career and sparked my interest in organic and medicinal chemistry as a student. I first realized that I had the ability to make my own contribution to science while conducting research under Dr. Heba's supervision, and it was under her mentorship that I recognized my desire to further pursue academic research in her Lab.

I would like to thank Professor Gamal Omran, Prof. of biochemistry and Dean of the faculty of pharmacy damanhour university, for his understanding and support that gave me strength and confidence when I needed it most, and for that, I thank you.

I would like to thank my mother, father, brothers, and sister for their efforts, support, and encouragement. Without their support, my success would not have been possible. Last but not least, my gratitude goes to my wife for her great support, continuous assistance, and encouragement through these years. Thank you for taking care of everything during this long journey.

Table of Contents

1. INTRODUCTION	1
1.1. Overview	2
1.2. Indazoles As Natural Products	3
1.3. Known Therapeutically Active Compounds Based on Indazole	4
1.3.1. Approved Drugs	4
1.3.2. Under Clinical Trials Drugs	6
1.3.3. Investigational Drugs	7
1.4. Pharmacological activities of Indazole Derivatives	8
1.4.1. Anti-Tumor Protein Kinase Inhibitors	8
1.4.1.1. Indazole Derivatives as Epidermal Growth Factor Receptor (EGFR) Inhibitors	8
1.4.2. Indazole Derivatives as Fibroblast Growth Factor Receptor (FGFR) Inhibitors	10
1.4.3. Indazole Derivatives as Vascular Endothelial Growth Factor Receptors (VEGFRs) Inhibitors	12
1.4.4. Indazole Derivatives as Polo-Like Kinase (PLK) Inhibitors	13
1.4.5. Indazole Derivatives as Aurora Kinase Inhibitors	15
1.4.6. Indazole Derivatives as Cyclin-Dependent Kinase (CDK) Inhibitors	17
1.4.7. Indazole Derivatives as Tyrosine Threonine Kinase (TTK) Inhibitors	18
1.4.8. Indazole Derivatives as Inhibitors of Mitogen-Activated Protein Kinases (MAPK) Pathway	20
1.4.9. Indazole Derivatives as Inhibitors of Proviral Insertion Site for Moloney Murine Lymphoma Virus (Pim) Kinases	22
1.4.10. Indazole Derivatives as Inhibitors of Phosphatidylinositol-3-Kinases (PI3Ks) And 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1)	23
1.4.2. Indazole Derivatives as Inhibitors of Hypoxia Inducible Factor-1 (HIF-1)	25
1.4.3. Indazole Derivatives as Selective Estrogen Receptor Degradar (SERD)	26
1.4.4. Indazole Derivatives as Histone Deacetylase Inhibitors (HDACi)	28
1.4.5. Antibacterial Activity	31
1.4.6. Anti-Inflammatory Activity	32
1.4.6.1. Indazoles as Non-Steroidal Glucocorticoid Receptor (GR) Modulator	32
1.4.6.2. Indazoles as Non-Steroidal Anti-Inflammatory Drug (NSAID)	35
1.4.7. Inhibitor of Human Neutrophil Elastase (HNE)	36
1.4.8. Inhibitor of Ketohexokinase (KHK)	37
1.4.9. Estrogen Receptor β (ER- β) Selective Ligands	38

1.4.10. Antiplatelet Activity.....	39
1.4.11. Anti-HIV	39
1.4.11.1. Indazole Derivatives as HIV Protease Inhibitors	39
1.4.11.2. Indazole Derivatives as Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTIs).....	41
1.4.12. Anti-Diabetic Activity.....	41
2. RESEARCH OBJECTIVES	43
2.1. Part 1: Structure Based Design and Synthesis of Conformationally Constrained Derivatives of Propylpyrazoletriol (PPT) With Antiestrogenic Activity.....	46
2.1.1. Development of Antiestrogens.....	46
2.1.2. Rational Design of Indazole Derivatives as Antiestrogens.....	49
2.1.3. Synthetic Schemes for Synthesis of The Designed Compounds	52
2.2. Part 2: Trisubstituted Indazoles with Potential Therapeutic Activities.....	55
2.2.1. Background	55
2.2.2. Rational Design of Trisubstituted Indazoles	55
2.2.3. Synthetic Schemes for Synthesis of The Designed Compounds	56
2.3. Part 3: Structure Based Design and Synthesis of 1,3-Diarylindazole Derivatives as HDAC6 Selective Inhibitors.	59
2.3.1. Development of HDAC Inhibitors	59
2.3.2. Rationale and Design	62
2.3.3. Synthetic Schemes for Synthesis of The Designed Compounds	65
3. RESULTS and DISCUSSION.....	66
3.1. Part 1: Chemical Synthesis of Scheme 1 and Scheme 2 Compounds (1-9) and (10a-i).68	
3.1.1. (<i>E</i>)-6-Methoxy-2-(4-methoxybenzylidene)-3,4-dihydronaphthalen-1(2 <i>H</i>)-one (1).....	68
3.1.2. 2-(4-Substituted)-7-methoxy-3-(4-methoxyphenyl)-3,3a,4,5-tetrahydro-2 <i>H</i> -benzo[<i>g</i>]indazoles (2a-c).....	68
3.1.3. 2-(4-Substitutedphenyl)-7-methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazoles (3a-c).....	69
3.1.4. 7-Methoxy-3-(4-methoxyphenyl)-2-(4-nitrophenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazole (4)	70
3.1.5. 4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)aniline (5)	70
3.1.6. <i>N</i> -(4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)phenyl)acetamide (6)	71
3.1.7. Ethyl 4-(7-methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzoate (7)	71

3.1.8. 4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzoic acid (8)	72
3.1.9. 4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzohydrazide (9)	73
3.1.10. 2-(4-Substitutedphenyl)-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-7-ol (10a-i).....	73
3.2. Biological Evaluation.....	74
3.2.1. In-vivo Assay: Uterotrophic Assay	74
3.2.2. In-vivo Assay: Anti-uterotrophic Assay	76
3.2.3. In-vitro Assay: Cytotoxicity Assay Against MCF-7, T-47D and SKOV-3 Cancer Cell Lines	80
3.3. Molecular Docking	82
3.4. Part 2: Chemical Synthesis of Scheme 3 Compounds (11-15, 16a-f) and Scheme 4 Compounds (17a-c, 18a-d, 19a-g).....	87
3.4.1. 1 <i>H</i> -Indazole-3-carboxylic acid (11).....	87
3.4.2. 5-Nitro-1 <i>H</i> -indazole-3-carboxylic Acid (12).....	88
3.4.3. Ethyl 5-nitro-1 <i>H</i> -indazole-3-carboxylate (13)	89
3.4.4. Ethyl 5-nitro-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylate (14).....	89
3.4.5. Ethyl 5-amino-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylate (15) ...	90
3.4.6. Ethyl 5-substituted amido-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylate (16a-f).....	91
3.4.7. Ethyl 5-(2-substituted acetamido)-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylates (17a-c).....	92
3.4.8. Ethyl 5-(2-substituted acetamido)-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylate (18a-d)	93
3.4.9. Ethyl 5-(2-substituted sulfanylacetamido)-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylate (19a-g)	93
3.5. Biological Evaluation.....	94
3.5.1. In-vitro Antimicrobial Screening	94
3.5.2. In-vitro Anticancer Screening	95
3.5.3. In-vitro Inhibition of Human Neutrophil Elastase (HNE)	100
3.6. Part 3: Chemical Synthesis of Scheme 5 compounds (20-31)	103
3.6.1. Ethyl 4-(2-(diphenylmethylene)hydrazinyl)benzoate (20)	103
3.6.2. Ethyl 4-(3-phenyl-1 <i>H</i> -indazol-1-yl)benzoate (21).....	103
3.6.3. <i>N</i> -Hydroxy-4-(3-phenyl-1 <i>H</i> -indazol-1-yl)benzamide (22).....	104
3.6.4. 4-(3-Phenyl-1 <i>H</i> -indazol-1-yl)benzoic acid (23)	104
3.6.5. <i>N</i> -(2-Substituted phenyl)-4-(3-phenyl-1 <i>H</i> -indazol-1-yl)benzamide (24a-c)	105

3.6.6.	4-(3-Phenyl-1 <i>H</i> -indazol-1-yl)benzohydrazide (25)	105
3.6.7.	1-Substituted 2-(4-(3-phenyl-1 <i>H</i> -indazol-1-yl)benzoyl)hydrazine (26a,b)	106
3.6.8.	5-(4-(3-Phenyl-1 <i>H</i> -indazol-1-yl)phenyl)-1,3,4-oxadiazole-2(3 <i>H</i>)-thione (27) ..	107
3.6.9.	5-(4-(3-Phenyl-1 <i>H</i> -indazol-1-yl)phenyl)-1,3,4-thiadiazole-2(3 <i>H</i>)-thione (28) ..	107
3.6.10.	4-Amino-5-(4-(3-phenyl-1 <i>H</i> -indazol-1-yl)phenyl)-2,4-dihydro-3 <i>H</i> -1,2,4-triazole-3-thione (29).....	108
3.6.11.	4-(3-Phenyl-1 <i>H</i> -indazol-1-yl)benzaldehyde (30)	109
3.6.12.	(<i>E</i>)-3-(4-(3-Phenyl-1 <i>H</i> -indazol-1-yl)phenyl)acrylic acid (31).....	110
3.7.	Biological Evaluation.....	110
3.7.1.	In-vitro Anticancer Screening.....	110
3.7.2.	In-vitro Cytotoxic Activity Against Selected Cancer Cell Lines.....	115
3.7.3.	In-vitro HDAC Inhibitory Activity	116
3.7.4.	In-vitro Measurement of Potential HDAC6 Inhibitory Activity (IC ₅₀)	117
3.7.5.	Docking on HDAC6 Crystal Structure	118
4.	CONCLUSION.....	120
5.	EXPERIMENTAL	126
5.1.	Part 1: Synthetic Details for Scheme 1 compounds (1-9) and Scheme 2 compounds (10a-i).....	128
5.1.1.	(<i>E</i>)-6-Methoxy-2-(4-methoxybenzylidene)-3,4-dihydronaphthalen-1(2 <i>H</i>)-one(1).....	128
5.1.2.	2-(4-Substituted)-7-methoxy-3-(4-methoxyphenyl)-3,3a,4,5-tetrahydro-2 <i>H</i> -benzo[<i>g</i>]indazoles (2a-c).....	128
5.1.2.1.	7-Methoxy-3-(4-methoxyphenyl)-2-phenyl-3,3a,4,5-tetrahydro-2 <i>H</i> -benzo[<i>g</i>]indazole (2a)	129
5.1.2.2.	2-(4-Chlorophenyl)-7-methoxy-3-(4-methoxyphenyl)-3,3a,4,5-tetrahydro-2 <i>H</i> -benzo[<i>g</i>]indazole (2b).....	129
5.1.2.3.	4-(7-Methoxy-3-(4-methoxyphenyl)-3,3a,4,5-tetrahydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzenesulfonamide (2c)	130
5.1.3.	2-(4-Substituted phenyl)-7-methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazoles (3a-c).....	131
5.1.3.1.	7-Methoxy-3-(4-methoxyphenyl)-2-phenyl-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazole (3a).....	131
5.1.3.2.	2-(4-Chlorophenyl)-7-methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazole (3b).....	132
5.1.3.3.	4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzenesulfonamide (3c)	132
5.1.4.	7-Methoxy-3-(4-methoxyphenyl)-2-(4-nitrophenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazole (4)	133

5.1.5.	4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)aniline (5).....	134
5.1.6.	<i>N</i> -(4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)phenyl)acetamide (6)	135
5.1.7.	Ethyl 4-(7-methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzoate (7)	136
5.1.8.	4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzoic acid (8)	138
5.1.9.	4-(7-Methoxy-3-(4-methoxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzohydrazide (9)	139
5.1.10.	2-(4-Substitutedphenyl)-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-7-ol (10a-i).....	140
5.1.10.1.	3-(4-Hydroxyphenyl)-2-phenyl-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-7-ol (10a).....	140
5.1.10.2.	2-(4-Chlorophenyl)-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-7-ol (10b)	141
5.1.10.3.	4-(7-Hydroxy-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzenesulfonamide (10c)	142
5.1.10.4.	3-(4-Hydroxyphenyl)-2-(4-nitrophenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-7-ol (10d)	142
5.1.10.5.	2-(4-Aminophenyl)-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-7-ol (10e)	143
5.1.10.6.	<i>N</i> -(4-(7-Hydroxy-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)phenyl)acetamide (10f)	144
5.1.10.7.	Ethyl 4-(7-Hydroxy-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzoate (10g).....	144
5.1.10.8.	4-(7-Hydroxy-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzoic acid (10h)	145
5.1.10.9.	4-(7-Hydroxy-3-(4-hydroxyphenyl)-4,5-dihydro-2 <i>H</i> -benzo[<i>g</i>]indazol-2-yl)benzohydrazide (10i).....	146
5.2.	Part 2: Synthetic Details for Scheme 3 compounds (11 - 16a-f) and Scheme 4 compounds (17a-c, 18a-d, and 19a-g).....	147
5.2.1.	1 <i>H</i> -Indazole-3-carboxylic acid (11).....	147
5.2.2.	5-Nitro-1 <i>H</i> -indazole-3-carboxylic Acid (12).....	149
5.2.3.	Ethyl 5-nitro-1 <i>H</i> -indazole-3-carboxylate (13)	149
5.2.4.	Ethyl 5-nitro-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylate (14)....	150
5.2.5.	Ethyl 5-amino-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylate (15) .	151
5.2.6.	Ethyl 5-substituted amido-1-(tetrahydro-2 <i>H</i> -pyran-2-yl)-1 <i>H</i> -indazole-3-carboxylates (16a-f)	152